Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
Esperion (NASDAQ: ESPR) has reached a settlement agreement with Accord Healthcare Inc. regarding patent litigation over NEXLETOL, a bempedoic acid medication. Under the agreement, Accord Healthcare has committed not to market a generic version of NEXLETOL in the United States before April 19, 2040, except under specific limited circumstances.
The company continues to pursue patent litigation against several other defendants, including Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories, MSN Pharmaceuticals, Renata Limited, and Sandoz. The outcome of these ongoing patent disputes remains uncertain regarding potential generic versions of NEXLETOL and NEXLIZET entering the U.S. market before 2040.
Esperion (NASDAQ: ESPR) has appointed Craig Thompson, current CEO of Cerevance, to its Board of Directors as an independent director, expanding the board to eight members. Thompson brings over 20 years of biopharmaceutical industry leadership experience and currently serves as CEO of Cerevance, a clinical-stage biotechnology company.
Thompson's extensive experience includes leadership roles at several pharmaceutical companies, notably serving as President & CEO of Neurana Pharmaceuticals, COO at Tetraphase Pharmaceuticals, and Chief Commercial Officer at Trius Therapeutics, where he was involved in its $700+ million acquisition by Cubist Pharmaceuticals. His background also includes senior positions at Pfizer and Merck & Co., where he led significant cardiovascular product initiatives.
Esperion (NASDAQ: ESPR) has announced its participation in two major investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4 at 1:25 p.m. ET, and the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET.
The company, a commercial stage biopharmaceutical firm, specializes in FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through commercial execution and international partnerships.
Esperion (NASDAQ: ESPR) has reached a settlement agreement with Micro Labs USA, Inc. and its affiliate regarding patent litigation over NEXLETOL. The settlement prevents Micro Labs from marketing a generic version of NEXLETOL in the United States before April 19, 2040, except under specific limited circumstances. The agreement resolves the litigation initiated by Esperion in response to Micro Labs' Abbreviated New Drug Application (ANDA). However, patent litigation continues with eight other defendants, including Accord Healthcare, Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories, Hetero USA, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc., with no guarantee of preventing generic versions before 2040.
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference scheduled for May 20, 2025, at 10 a.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days after the presentation.
Esperion is a commercial-stage biopharmaceutical company that develops FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Esperion (NASDAQ: ESPR) has granted 49,300 restricted stock units (RSUs) to 15 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to continued employment. The grants were made as employment inducements under NASDAQ Rule 5635(c)(4).
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi).
Esperion Therapeutics (NASDAQ: ESPR) has entered into a license and distribution agreement with HLS Therapeutics for exclusive commercialization rights of NEXLETOL and NEXLIZET in Canada. The agreement includes an upfront payment, milestone payments up to $5 million, and tiered royalties on product sales. Esperion will supply the finished product at a profitable transfer price.
The partnership aims to address a significant market, as approximately 2.6 million Canadian adults live with diagnosed heart disease, which is the second leading cause of death in Canada. HLS will handle commercialization, reimbursement, and marketing responsibilities in Canada, while Esperion maintains product supply duties.
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming Citizens Life Sciences Conference scheduled for May 8, 2025, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days.
Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
